Wuhan Hiteck Biological Pharma Co Ltd (300683) — Net Asset Quality Index
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Net Asset Quality Index of 85.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.64 Billion minus total liabilities of CN¥393.09 Million yields net assets of CN¥2.24 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Wuhan Hiteck Biological Pharma Co Ltd (300683) liquidity interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Wuhan Hiteck Biological Pharma Co Ltd Net Asset Quality Index Over Time (2013–2024)
This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 85.1%, representing net assets of CN¥2.24 Billion against total assets of CN¥2.64 Billion CNY. Explore how efficiently does Wuhan Hiteck Biological Pharma Co Ltd generate cash to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below presents the year-by-year Net Asset Quality Index for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Wuhan Hiteck Biological Pharma Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 82.1% | CN¥2.41 Billion | CN¥2.94 Billion | CN¥525.05 Million | ▼ -1.9 pp |
| 2023 | 84.0% | CN¥2.50 Billion | CN¥2.97 Billion | CN¥475.73 Million | ▼ -2.3 pp |
| 2022 | 86.3% | CN¥2.34 Billion | CN¥2.71 Billion | CN¥371.20 Million | ▼ -0.6 pp |
| 2021 | 86.9% | CN¥2.34 Billion | CN¥2.70 Billion | CN¥354.46 Million | ▲ +8.0 pp |
| 2020 | 78.9% | CN¥1.72 Billion | CN¥2.19 Billion | CN¥461.62 Million | ▼ -2.3 pp |
| 2019 | 81.1% | CN¥1.76 Billion | CN¥2.17 Billion | CN¥409.03 Million | ▲ +1.8 pp |
| 2018 | 79.3% | CN¥1.71 Billion | CN¥2.16 Billion | CN¥445.77 Million | ▼ -6.8 pp |
| 2017 | 86.1% | CN¥1.64 Billion | CN¥1.91 Billion | CN¥265.62 Million | ▲ +18.4 pp |
| 2016 | 67.7% | CN¥703.35 Million | CN¥1.04 Billion | CN¥335.87 Million | ▼ -0.7 pp |
| 2015 | 68.4% | CN¥596.76 Million | CN¥872.49 Million | CN¥275.74 Million | ▲ +1.4 pp |
| 2014 | 67.0% | CN¥536.59 Million | CN¥801.37 Million | CN¥264.78 Million | ▲ +9.2 pp |
| 2013 | 57.7% | CN¥254.64 Million | CN¥441.07 Million | CN¥186.42 Million | — |